Psychogenics, Amylin create new development company
PsychoGenics and Amylin Pharmaceuticals have formed Psylin Neurosciences, a new company that will focus on the discovery and development of peptide hormones for treatment of psychiatric disorders. PsychoGenics and Amylin participated equally in a Series A financing of Psylin to fund the company for approximately the next two years.
"Given the richness of the unique PHORMOL library, we expect several drug candidates to emerge from this collaboration and the creation of Psylin affords both companies the opportunity to pursue a new area of research while maintaining their corporate focus," says Emer Leahy, PhD, president and CEO of PsychoGenics.
- see the release on the new company
Related Articles:
PsychoGenics announces agreement with Eli Lilly. Release
Amylin reports weight-loss success with Symlin. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
